Cabinet nod for India-Uzbekistan MoU on cooperation in pharma sector

New Delhi: The Cabinet Wednesday approved a memorandum of understanding (MoU) to be signed between India and Uzbekistan to increase cooperation in the areas of trade, industry, and research and development of pharmaceutical products. The Cabinet also gave it nod to another MoU between India and Uzbekistan for the establishment of the Uzbek-Indian free pharmaceutical zone in the Andijan region of Uzbekistan.

The MoUs will be signed during the visit of President of Uzbekistan to India on October 1, 2018, an official statement said.

In view of the importance of the growth of the pharma industry in both countries and importance of mutual cooperation in trade, production,research and development in the pharmaceutical sector, both governments have been trying to establish a formal mechanism of bilateral cooperation, it added.

The MoU will explore the possibilities for the production of medicines, including active pharmaceutical ingredients (APIs) in different therapeutic segments in both countries, the statement said.

“It will also exchange information on trade and registration procedures, legal and regulatory requirements for export and import of pharmaceuticals products, including APIs,” it added.

The MoU will increase cooperation with Uzbekistan in the areas of trade, industry and research and development of pharma products, the statement said.

The MoU will facilitate Indian pharmaceutical and biopharmaceutical companies to invest in and establish production facilities in the Uzbek-Indian free pharma zone for manufacture of pharmaceutical products, a separate release said.

  • Related Posts

    Cancer cure must not be hostage to Big Pharma

    In recent years, immunotherapy has expanded the limits of cancer treatment. Therapies that harness the body’s immune system to fight malignant cells have improved survival rates in cancers once considered…

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Pune:- A woman, 34, dia­gnosed with poly­cystic ovary syn­drome, or PCOS, as a teen­ager, saw her first nat­ural men­strual cycle in Feb­ru­ary—six months after start­ing Moun­jaro for weight man­age­ment. This…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

    Patna HC Rules Phenothiazine & Promethazine Not Narcotic Or Psychotropic Substances Under NDPS Act

    COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients

    COMT Inhibitors May Fuel Gut Bacteria That Degrade Levodopa In Parkinson’s Patients